Latest Breaking News On - Swedish psoriasis association - Page 1 : comparemela.com

(0) STOCKHOLM, April 22, 2021 /PRNewswire/ Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the company s drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for commencement of the Phase III study. As Lipidor has previously announced, the main purpose of the study is to compare the therapeutic efficacy of AKP02 with existing medicines for mild to moderate psoriasis. Results from the study are expected in the first half of 2022. AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor s patented AKVANO technology. The aim with AKP02 is to offer a patient-friendly, spray-based treatment for mild to moderate plaque psoriasis.

Ola holmlundSwedish psoriasis associationErik penser bankCadila pharmaceuticalsIndian medical products agencyNasdaq first northஏறிக் பென்சர் வங்கிகாடிலா மருந்துகள்நாஸ்டாக் முதல் வடக்கு